Log in

NASDAQ:CDXCChromadex Stock Price, Forecast & News

-0.06 (-1.16 %)
(As of 08/4/2020 04:00 PM ET)
Today's Range
Now: $5.10
50-Day Range
MA: $4.81
52-Week Range
Now: $5.10
Volume276,186 shs
Average Volume350,923 shs
Market Capitalization$313.55 million
P/E RatioN/A
Dividend YieldN/A
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.
Read More
Chromadex logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.71 out of 5 stars

Industry, Sector and Symbol

Industry Medicinals & botanicals
Current SymbolNASDAQ:CDXC



Sales & Book Value

Annual Sales$46.29 million
Book Value$0.34 per share


Net Income$-32,150,000.00


Market Cap$313.55 million
Next Earnings Date8/6/2020 (Confirmed)
-0.06 (-1.16 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Chromadex (NASDAQ:CDXC) Frequently Asked Questions

How has Chromadex's stock been impacted by COVID-19 (Coronavirus)?

Chromadex's stock was trading at $3.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CDXC shares have increased by 38.6% and is now trading at $5.10.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Chromadex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chromadex

When is Chromadex's next earnings date?

Chromadex is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Chromadex

How can I listen to Chromadex's earnings call?

Chromadex will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Chromadex's earnings last quarter?

Chromadex Corp (NASDAQ:CDXC) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The business had revenue of $14.35 million for the quarter, compared to analyst estimates of $13.76 million. Chromadex had a negative net margin of 58.73% and a negative return on equity of 132.48%.
View Chromadex's earnings history

What price target have analysts set for CDXC?

3 equities research analysts have issued twelve-month price targets for Chromadex's stock. Their forecasts range from $6.00 to $7.00. On average, they anticipate Chromadex's stock price to reach $6.33 in the next year. This suggests a possible upside of 24.2% from the stock's current price.
View analysts' price targets for Chromadex

Has Chromadex been receiving favorable news coverage?

Media stories about CDXC stock have been trending somewhat negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chromadex earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term.
View the latest news about Chromadex

Are investors shorting Chromadex?

Chromadex saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 2,410,000 shares, an increase of 7.1% from the June 30th total of 2,250,000 shares. Based on an average daily volume of 463,500 shares, the short-interest ratio is currently 5.2 days. Currently, 6.6% of the company's stock are sold short.
View Chromadex's Current Options Chain

Who are some of Chromadex's key competitors?

What other stocks do shareholders of Chromadex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chromadex investors own include Heron Therapeutics (HRTX), Tilray (TLRY), TransEnterix (TRXC), Athersys (ATHX), Glu Mobile (GLUU), Axsome Therapeutics (AXSM), CELYAD SA/ADR (CYAD), Mesoblast (MESO), Sorrento Therapeutics (SRNE) and FuelCell Energy (FCEL).

Who are Chromadex's key executives?

Chromadex's management team includes the following people:
  • Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 51)
  • Mr. Robert N. Fried, CEO & Director (Age 59)
  • Mr. Kevin M. Farr, Chief Financial Officer (Age 61)
  • Mr. Ben Shichman, Chief Technology Officer
  • Dr. Matthew Roberts, Chief Scientific Officer & Sr. VP of Innovation

What is Chromadex's stock symbol?

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

Who are Chromadex's major shareholders?

Chromadex's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sycale Advisors NY LLC (0.59%), UBS Group AG (0.33%), Raymond James Financial Services Advisors Inc. (0.14%), Insight 2811 Inc. (0.05%) and SG Americas Securities LLC (0.04%). Company insiders that own Chromadex stock include Kevin M Farr, Robert N Fried and Stephen A Block.
View institutional ownership trends for Chromadex

Which major investors are selling Chromadex stock?

CDXC stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Chromadex

Which major investors are buying Chromadex stock?

CDXC stock was bought by a variety of institutional investors in the last quarter, including Sycale Advisors NY LLC, SG Americas Securities LLC, and Insight 2811 Inc.. Company insiders that have bought Chromadex stock in the last two years include Kevin M Farr, and Robert N Fried.
View insider buying and selling activity for Chromadex

How do I buy shares of Chromadex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chromadex's stock price today?

One share of CDXC stock can currently be purchased for approximately $5.10.

How big of a company is Chromadex?

Chromadex has a market capitalization of $313.55 million and generates $46.29 million in revenue each year. The company earns $-32,150,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chromadex employs 100 workers across the globe.

What is Chromadex's official website?

The official website for Chromadex is www.chromadex.com.

How can I contact Chromadex?

Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.